Press Releases

– Conference Call Today at 1:30 p.m. ET SEATTLE --(BUSINESS WIRE)--Nov. 9, 2023-- Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications

SEATTLE --(BUSINESS WIRE)--Nov. 6, 2023-- Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter ended September 30, 2023 , on Thursday, November 9, 2023 , after the market closes. Omeros management will host a conference call and

-- Poster Presentation Slated for Upcoming Annual Meeting of the American Society of Hematology -- SEATTLE --(BUSINESS WIRE)--Nov. 3, 2023-- Omeros Corporation (Nasdaq: OMER) today announced online publication of a report detailing treatment with narsoplimab of 15 adult and pediatric patients with

-- New and Updated Data from Ongoing Phase 2 Study of OMS906 in Paroxysmal Nocturnal Hemoglobinuria Selected for Podium Presentation -- SEATTLE --(BUSINESS WIRE)--Nov. 2, 2023-- Omeros Corporation (Nasdaq: OMER) today announced that two abstracts directed to OMS906, Omeros’ investigational

SEATTLE --(BUSINESS WIRE)--Oct. 19, 2023-- Omeros Corporation (Nasdaq: OMER) today announced that Andreas Grauer , M.D., has been named Omeros’ chief medical officer. In his new role, Dr. Grauer will be responsible for guiding all clinical activities globally for the company, including clinical

The ARTEMIS-IGAN trial did not reach statistical significance on the primary endpoint of reduction in proteinuria from baseline compared to placebo Proteinuria reduction in the placebo group was substantially greater than reported in other IgA nephropathy clinical trials Webcast conference call

– Conference Call Today at 8:30 a.m. ET – SEATTLE --(BUSINESS WIRE)--Aug. 9, 2023-- Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications

SEATTLE --(BUSINESS WIRE)--Aug. 4, 2023-- Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter ended June 30, 2023 , on Wednesday, August 9, 2023 , before the market opens. Omeros management will host a conference call and webcast that

SEATTLE --(BUSINESS WIRE)--Jun. 21, 2023-- Omeros Corporation (Nasdaq: OMER), today announced that the company will host a live webcast of its Annual Meeting of Shareholders, which will be held virtually on Friday, June 23, 2023 , starting at 10:00 a.m. Pacific Time .

SEATTLE --(BUSINESS WIRE)--Jun. 12, 2023-- Omeros Corporation (Nasdaq: OMER) today announced that the slides presented yesterday in the “late-breaker” session at the 2023 European Hematology Association (EHA) Congress in Frankfurt, Germany are now available on Omeros’ website .

– Late-breaking abstract detailing interim data from ongoing clinical trial of OMS906 in treatment-naïve PNH patients selected for June 11, 2023 oral presentation – SEATTLE --(BUSINESS WIRE)--Jun. 1, 2023-- Omeros Corporation (Nasdaq: OMER) today announced that data from a pre-specified interim

– Conference Call Today at 4:30 p.m. ET – SEATTLE --(BUSINESS WIRE)--May 9, 2023-- Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications

SEATTLE --(BUSINESS WIRE)--May 4, 2023-- Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its first quarter financial results for the period ended March 31, 2023 , on Tuesday, May 9, 2023 , after the market closes. Omeros management will host a conference call and

At lowest planned subcutaneous dose, Omeros’ MASP-3 inhibitor OMS906 showed clinically and statistically significant improvements in hemoglobin and LDH, which were seen early and maintained throughout the observation period Following 2 doses of OMS906, all patients achieved an increase in

–   Directs Company to Advance its Lead Proprietary PDE7 Inhibitor to Treat Cocaine Use Disorder – SEATTLE --(BUSINESS WIRE)--Apr. 10, 2023-- Omeros Corporation (Nasdaq: OMER) today announced that it has been awarded a grant from the National Institute on Drug Abuse (NIDA), part of the National

– Conference Call Today at 4:30 p.m. ET – SEATTLE --(BUSINESS WIRE)--Mar. 13, 2023-- Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications

SEATTLE --(BUSINESS WIRE)--Mar. 10, 2023-- Omeros Corporation (Nasdaq: OMER), in response to investor inquiries, is confirming that it has no banking or other financial relationship with Silicon Valley Bank . Omeros previously maintained a line of credit with Silicon Valley Bank , which the company

SEATTLE --(BUSINESS WIRE)--Mar. 7, 2023-- Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its fourth quarter and year-end financial results for the period ended December 31, 2022 , on Monday, March 13, 2023 , after the market closes.

– OMIDRIA ® -Related Payment Expected to Provide Operating Capital into at Least 2025 – SEATTLE --(BUSINESS WIRE)--Feb. 6, 2023-- Omeros Corporation (Nasdaq: OMER) today announced that Rayner Surgical, Inc. (“Rayner”) has paid the $200 million milestone payment due to Omeros under the Asset